Understanding how Candida albicans hides from the immune system
Regulation of ß(1,3)-glucan exposure in Candida albicans
This study is looking at how the fungus Candida albicans hides from our immune system and how certain antifungal medications can help make it more visible, with the goal of finding better ways to treat Candida infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Knoxville NIH-funded |
| Lab location | 1 site (Knoxville, United States) |
| Project ID | NIH-10828783 on NIH RePORTER |
What this research studies
This research investigates how the fungus Candida albicans can evade detection by the human immune system, which is crucial for developing better treatments for infections. The study focuses on a specific carbohydrate, ß(1,3)-glucan, that the immune system recognizes to fight off fungal infections. Researchers will explore how antifungal drugs, like caspofungin, affect the exposure of ß(1,3)-glucan and how this impacts the virulence of the fungus. By understanding these mechanisms, the research aims to improve therapeutic strategies against Candida infections.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with invasive Candida infections or those at high risk for such infections.
Not a fit: Patients with non-fungal infections or those not at risk for Candida infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective antifungal treatments that enhance the immune response against Candida infections.
How similar studies have performed: Previous research has shown that understanding fungal virulence factors can lead to significant advancements in antifungal therapies, indicating a promising avenue for this investigation.
Where this research is happening
Knoxville, United States
- University of Tennessee Knoxville — Knoxville, United States (Active)
Researchers
- Principal investigator: Reynolds, Todd B — University of Tennessee Knoxville
- Study coordinator: Reynolds, Todd B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.